Biotech · Private company
Millennium Pharmaceuticals, Inc.
Track this companyFree. Adds Millennium Pharmaceuticals, Inc. to your Dealase workspace and tells you when its record changes.
Clinical trials257 recruiting or active
Pipeline programs13From trials and the company's site
Disclosed deals0None found yet
Cash runwayNot availablePrivate: no SEC financials
Pipeline13
- CyclophosphamidePhase 3 · Relapsed or Refractory Systemic Light Chain AmyloidosisClinicalTrials.gov · fetched Nov 12, 2026
- DexamethasonePhase 3 · Relapsed or Refractory Systemic Light Chain AmyloidosisClinicalTrials.gov · fetched Nov 12, 2026
- IXAZOMIBPhase 3 · Relapsed or Refractory Systemic Light Chain AmyloidosisClinicalTrials.gov · fetched Nov 12, 2026
- LenalidomidePhase 3 · Relapsed or Refractory Systemic Light Chain AmyloidosisClinicalTrials.gov · fetched Nov 12, 2026
- MelphalanPhase 3 · Relapsed or Refractory Systemic Light Chain AmyloidosisClinicalTrials.gov · fetched Nov 12, 2026
- ThalidomidePhase 3 · Relapsed or Refractory Systemic Light Chain AmyloidosisClinicalTrials.gov · fetched Nov 12, 2026
- Brentuximab vedotinPhase 2 · Relapsed or Refractory Hodgkin LymphomaClinicalTrials.gov · fetched Nov 12, 2026
- ipilimumabPhase 1 · MelanomaClinicalTrials.gov · fetched Nov 12, 2026
- nivolumabPhase 1 · MelanomaClinicalTrials.gov · fetched Nov 12, 2026
- TAK-079Phase 1 · Systemic Lupus ErythematosusClinicalTrials.gov · fetched Nov 12, 2026
- TAK-202Phase 1 · MelanomaClinicalTrials.gov · fetched Nov 12, 2026
- TAK-580Phase 1 · MelanomaClinicalTrials.gov · fetched Nov 12, 2026
- vedolizumabPhase 1 · MelanomaClinicalTrials.gov · fetched Nov 12, 2026
Clinical trials25
- A Study to Evaluate the Safety, Pharmacokinetics (PK), and Pharmacodynamics (PD) of TAK-079 in Combination With Standard Background Therapy in Participants With Moderate to Severe Systemic Lupus Erythematosus (SLE)PHASE1 · COMPLETED · started Nov 26, 2018ClinicalTrials.gov NCT03724916 · fetched Nov 12, 2026
- Pulmonary Physiology and Systemic Inflammatory in EO Pulmonary Events With Brigatinib Use in NSCLC and Other DiseasesCOMPLETED · started Feb 22, 2018ClinicalTrials.gov NCT03389399 · fetched Nov 12, 2026
- Ixazomib Citrate, Lenalidomide, Dexamethasone, and Zoledronic Acid or Zoledronic Acid Alone After Radiation Therapy in Treating Patients With Solitary Plasmacytoma of BonePHASE3 · TERMINATED · started Nov 29, 2016ClinicalTrials.gov NCT02516423 · fetched Nov 12, 2026
- Ixazomib and Dexamethasone Versus Ixazomib, Dexamethasone and Lenalidomide, Randomized With NFKB2 RearrangementPHASE2 · COMPLETED · started Sep 1, 2016ClinicalTrials.gov NCT02765854 · fetched Nov 12, 2026
- Study to Evaluate the Safety, Tolerability, and Pharmacodynamics of Investigational Treatments in Combination With Standard of Care Immune Checkpoint Inhibitors in Participants With Advanced MelanomaPHASE1 · TERMINATED · started Jun 22, 2016ClinicalTrials.gov NCT02723006 · fetched Nov 12, 2026
- Ixazomib Citrate and Rituximab in Treating Patients With Indolent B-cell Non-Hodgkin LymphomaPHASE2 · ACTIVE_NOT_RECRUITING · started May 19, 2016ClinicalTrials.gov NCT02339922 · fetched Nov 12, 2026
- Ixazomib (MLN9708) and Dexamethasone in High Risk Smoldering Multiple Myeloma: A Clinical and Correlative Pilot StudyPHASE1 · COMPLETED · started Feb 1, 2016ClinicalTrials.gov NCT02697383 · fetched Nov 12, 2026
- Phase II Study of Efficacy and Safety of Lenalidomide, Subcutaneous Bortezomib and Dexamethasone Therapy for Newly Diagnosed Multiple MyelomaPHASE2 · COMPLETED · started Dec 1, 2015ClinicalTrials.gov NCT02441686 · fetched Nov 12, 2026
- Study to Compare Alisertib With Paclitaxel vs. Paclitaxel Alone in Metastatic or Locally Recurrent Breast CancerPHASE2 · COMPLETED · started Feb 12, 2015ClinicalTrials.gov NCT02187991 · fetched Nov 12, 2026
- Velcade and Lenalidomide in Patients With Relapsed AML and MDS After Allogeneic Stem Cell TransplantationPHASE1 · COMPLETED · started Feb 1, 2015ClinicalTrials.gov NCT02312102 · fetched Nov 12, 2026
- Alisertib and Fractionated Stereotactic Radiosurgery in Treating Patients With Recurrent High Grade GliomasPHASE1 · COMPLETED · started Jan 30, 2015ClinicalTrials.gov NCT02186509 · fetched Nov 12, 2026
- Phase II Study of IRD (Ixazomib, Lenalidomide, Dexamethasone) Post Autologous Stem Cell Transplantation Followed by Maintenance Ixazomib or Lenalidomide for Multiple MyelomaPHASE2 · ACTIVE_NOT_RECRUITING · started Jan 20, 2015ClinicalTrials.gov NCT02253316 · fetched Nov 12, 2026
- Phase 2 Study of Alisertib Therapy for Rhabdoid TumorsPHASE2 · ACTIVE_NOT_RECRUITING · started May 14, 2014ClinicalTrials.gov NCT02114229 · fetched Nov 12, 2026
- Response Adapted Therapy With Bortezomib/Dexamethasone Followed by Addition of Lenalidomide in Non Responders as Initial Treatment for Patients With Multiple MyelomaPHASE2 · COMPLETED · started Aug 6, 2013ClinicalTrials.gov NCT01919086 · fetched Nov 12, 2026
- Study of Dexamethasone Plus IXAZOMIB (MLN9708) or Physicians Choice of Treatment in Relapsed or Refractory Systemic Light Chain (AL) AmyloidosisPHASE3 · TERMINATED · started Dec 26, 2012ClinicalTrials.gov NCT01659658 · fetched Nov 12, 2026
- Study of Brentuximab Vedotin (SGN-35) in Pediatric Participants With Relapsed or Refractory (r/r) Systemic Anaplastic Large-Cell Lymphoma or Hodgkin LymphomaPHASE1_PHASE2 · COMPLETED · started Apr 16, 2012ClinicalTrials.gov NCT01492088 · fetched Nov 12, 2026
- Randomized Trial of Lenalidomide, Bortezomib, Dexamethasone vs High-Dose Treatment With SCT in MM Patients up to Age 65PHASE3 · ACTIVE_NOT_RECRUITING · started Sep 1, 2010ClinicalTrials.gov NCT01208662 · fetched Nov 12, 2026
- Escalating Doses of Thalidomide in Conjunction With Bortezomib and HIgh Dose Melphalan for BSCTPHASE1_PHASE2 · COMPLETED · started May 11, 2010ClinicalTrials.gov NCT01242267 · fetched Nov 12, 2026
- UARK 2013-13, Total Therapy 4B - Formerly 2008-01 - A Phase III Trial for Low Risk MyelomaPHASE3 · ACTIVE_NOT_RECRUITING · started Jul 1, 2008ClinicalTrials.gov NCT00734877 · fetched Nov 12, 2026
- Bortezomib, Lenalidomide and Dexamethasone Combination Therapy in Patients With Newly Diagnosed Multiple MyelomaPHASE1_PHASE2 · ACTIVE_NOT_RECRUITING · started Sep 1, 2006ClinicalTrials.gov NCT00378105 · fetched Nov 12, 2026
- Bortezomib and Rituximab for Patients With Waldenstrom's MacroglobulinemiaPHASE2 · ACTIVE_NOT_RECRUITING · started Aug 2, 2006ClinicalTrials.gov NCT00492050 · fetched Nov 12, 2026
- Bortezomib After Combination Chemotherapy, Rituximab, and an Autologous Stem Cell Transplant in Treating Patients With Mantle Cell LymphomaPHASE2 · COMPLETED · started Jun 1, 2006ClinicalTrials.gov NCT00310037 · fetched Nov 12, 2026
- Study of VELCADE® With Mitoxantrone and Etoposide for LeukemiasPHASE1_PHASE2 · COMPLETED · started Jan 1, 2006ClinicalTrials.gov NCT00410423 · fetched Nov 12, 2026
- A Trial Using Velcade Plus Chemoradiation for Central Nervous System, Head and Neck, and Cervical Cancer PatientsPHASE1 · COMPLETED · started Sep 1, 2005ClinicalTrials.gov NCT00329589 · fetched Nov 12, 2026
- Study of Bortezomib and Docetaxel for Patients With Hormone Refractory Prostate CancerPHASE2 · TERMINATED · started Apr 30, 2005ClinicalTrials.gov NCT00183937 · fetched Nov 12, 2026